IMRA IMARA Inc.

24.02
-0.48  -2%
Previous Close 24.5
Open 25
52 Week Low 13.4
52 Week High 62.71
Market Cap $418,126,733
Shares 17,407,441
Float 7,709,052
Enterprise Value $260,763,540
Volume 49,744
Av. Daily Volume 36,277
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
IMR-687
Sickle cell disease
Phase 2a
Phase 2a
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
IMR-687
b-thalassemia
Phase 2b
Phase 2b
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
IMR-687 (Ardent)
Sickle cell disease (SCD)
Phase 2b
Phase 2b
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Lynette Hopkinson as Senior Vice President of Regulatory. Ms. Hopkinson joins Imara with 25 years of experience in the pharmaceutical and biotech industries, where she led global regulatory teams in strategy for multiple clinical development candidates and marketed products.

    "We are delighted to welcome Lyn to Imara; her expertise and understanding of global regulatory strategy and commercial affairs will be important as we continue to advance IMR-687 across…

    BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Lynette Hopkinson as Senior Vice President of Regulatory. Ms. Hopkinson joins Imara with 25 years of experience in the pharmaceutical and biotech industries, where she led global regulatory teams in strategy for multiple clinical development candidates and marketed products.

    "We are delighted to welcome Lyn to Imara; her expertise and understanding of global regulatory strategy and commercial affairs will be important as we continue to advance IMR-687 across multiple indications globally," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "Lyn also brings deep expertise in rare diseases, including most recently in cystic fibrosis, and importantly in CRISPR Cas-9 programs in sickle cell disease and beta thalassemia. Lyn is a key and timely addition to our leadership team."

    "I'm thrilled to join Imara at such an exciting time. The recent advancement of IMR-687 into Phase 2b clinical trials for patients with sickle cell disease and beta-thalassemia is a critical milestone and I look forward to collaborating with the leadership team on global regulatory and clinical strategy going forward," said Ms. Hopkinson.

    Prior to joining Imara, Ms. Hopkinson served as Vice President, Global Head of Cystic Fibrosis (CF) Regulatory Strategy and Commercial Regulatory Affairs at Vertex Pharmaceuticals. In this role, she oversaw early and late-stage development programs, as well as line-extension programs for marketed products, and managed a strategy team of global and regulatory leads responsible for the development and execution of regulatory strategy plans, as well as a team of commercial regulatory leads responsible for supporting multiple CF product launches. Ms. Hopkinson also served as Vertex's Vice President, Head of North America Regulatory Strategy and Commercial Affairs for marketed products as well as clinical development candidates, including the CRISPR Cas-9 programs in sickle cell disease and beta thalassemia. Before Vertex, Ms. Hopkinson held Regulatory Affairs roles of increasing responsibility at Eisai, Inc. and Genentech, Inc., including supporting the approvals of multiple new drugs including Halaven®, Fycompa®, Belviq® and Lucentis®. Ms. Hopkinson received her B. Pharm and Management Advancement certificate from the University of Witwatersrand in Johannesburg, South Africa. 

    About IMR-687

    IMR-687 is a highly selective and potent small molecule inhibitor of PDE9. PDE9 selectively degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule that plays a role in vascular biology. Lower levels of cGMP are found in people with SCD and beta-thalassemia and are associated with reduced blood flow, increased inflammation, greater cell adhesion and reduced nitric oxide mediated vasodilation.

    Blocking PDE9 acts to increase cGMP levels, which is associated with reactivation of fetal hemoglobin (HbF), a natural hemoglobin produced during fetal development. Increased levels of HbF in RBCs have been demonstrated to improve symptomology and substantially lower disease burden in both patients with SCD and patients with beta-thalassemia.

    About Imara

    Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.

    Cautionary Note Regarding Forward-Looking Statements

    Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the Company's plans, strategies and prospects. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the "Risk Factors" section of the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Media Contact:

    Gina Nugent

    Ten Bridge Communications

    617-460-3579

    Investor Contact:

    Michael Gray

    617-835-4061 



    Primary Logo

    View Full Article Hide Full Article
  2. Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia

    IMR-687 granted Orphan Drug designation from European Commission for sickle cell disease

    Company to host conference call and live webcast today at 8:30 a.m. ET

    BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today reported financial results for the third quarter ended September 30, 2020 and reviewed recent business highlights.

    "We continue to advance IMR-687 across multiple indications and as part of global, multi-center…

    Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia

    IMR-687 granted Orphan Drug designation from European Commission for sickle cell disease

    Company to host conference call and live webcast today at 8:30 a.m. ET

    BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today reported financial results for the third quarter ended September 30, 2020 and reviewed recent business highlights.

    "We continue to advance IMR-687 across multiple indications and as part of global, multi-center clinical trials, despite COVID-19," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "We have initiated patient dosing in our Phase 2b clinical trials of IMR-687 in both sickle cell disease and beta-thalassemia and have activated sites around the world. In addition, we also continued to make progress on the regulatory front as we were granted Orphan Drug designation by the European Commission for the treatment of patients with sickle cell disease."

    Dr. Ballal continued, "We have also made important progress on our Phase 2a open label extension clinical trial in adult patients with sickle cell disease. In August 2020, we reported initial data from the first two patients in this clinical trial who had received at least six-months of treatment. The data indicated potential benefits of IMR-687 with respect to reported vaso-occlusive crises trends, healthcare facility use and associated biomarkers. We plan to report additional data from these two patients at the annual American Society of Hematology 2020 virtual meeting in December 2020. Importantly, enrollment in the open label extension clinical trial has increased to 23 patients and we expect to report additional data during the first quarter of 2021 on approximately 10 to 15 patients from the OLE clinical trial."

            

    Recent Corporate Highlights and Updates

    • Patient Dosing Underway in Phase 2b Clinical Trials: Imara dosed the first patients in both its Ardent Phase 2b sickle cell disease (SCD) clinical trial and its Forte Phase 2b beta-thalassemia clinical trial. Imara plans to report formal interim analyses from the Ardent and Forte Phase 2b clinical trials when 33 and 30 patients, respectively, have completed 24 weeks of treatment. Due to COVID-19 related recruitment delays, the company expects to report interim data from the Ardent and Forte Phase 2b clinical trials in the second half of 2021 rather than the first half of 2021 as originally planned.



    • Completed Dosing in Phase 2a Clinical Trial: Imara completed dosing patients in the Phase 2a clinical trial in patients with SCD during the third quarter of 2020 and plans to report top-line data from this trial late in the fourth quarter of 2020. Imara also expects to report additional data from two patients in its ongoing Phase 2a open label extension (OLE) clinical trial in adult patients with SCD at the annual American Society of Hematology (ASH) 2020 virtual meeting in December 2020 as well as data from approximately 10 to 15 patients in the OLE clinical trial in the first quarter of 2021.



    • IMR-687 Granted Regulatory Designation: The European Commission granted IMR-687 Orphan Disease designation for the treatment of SCD. IMR-687 has previously been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for the treatment of patients with SCD.



    • Expanded Pipeline: Exploratory research indicating potential cardioprotective effects of IMR-687 in SCD and heart failure were presented at the 15th Annual Sickle Cell and Thalassemia Conference held virtually October 26-31, 2020. These results, which include analysis of a sub-set of SCD patients from the Phase 2a clinical trial, demonstrate that IMR-687 in combination with HU reduced N-terminal (NT)-pro hormone B-type natriuretic peptide (NT-proBNP), a biomarker used to measure cardiovascular risk. NT-proBNP is being measured as an exploratory endpoint in both the Ardent and Forte Phase-2b clinical trials. In addition, preclinical data in heart failure with preserved ejection fraction (HFpEF), also referred to as diastolic heart failure, were also presented, showing potential benefits of IMR-687 across several relevant cardiac biomarkers.

    Third Quarter 2020 Financial Results

    • Cash Position: Cash, cash equivalents and investments were $96.1 million as of September 30, 2020, as compared to cash, cash equivalents and investments of $28.9 million as of December 31, 2019.



    • Research and Development Expenses: Research and development expenses were $9.5 million for the third quarter of 2020, as compared to $5.1 million for the third quarter of 2019. The increase of $4.4 million was primarily related to the development and manufacturing of clinical materials, clinical research and oversight of the Company's clinical trials and investigative fees related to the development of IMR-687, as well as increased personnel-related and other research and development operational costs.



    • General and Administrative Expenses: General and administrative expenses were $3.0 million for the third quarter of 2020, as compared to $1.7 million for the third quarter of 2019. The increase of $1.2 million was primarily due to increased personnel-related and other general and administrative operational costs as a result of operating as a public company.



    • Net Loss Attributable to Common Stockholders: Net loss attributable to common stockholders was $12.4 million, or $0.72 per share, for the third quarter of 2020, as compared to a net loss of $6.6 million, or $9.43 per share, for the third quarter of 2019.

    Financial Guidance

    The Company currently expects that its full-year 2020 research and development expenses will range between $32 million and $37 million rather than the $35 million to $40 million originally estimated and that its full-year 2020 general and administrative expenses will range between $9 million and $10 million. The Company expects that its cash, cash equivalents and investments as of September 30, 2020, will be sufficient to enable it to fund its planned operations into mid-2022.

    Conference Call and Webcast Information

    Imara will host a conference call and live webcast today at 8:30 a.m. ET to discuss its third quarter 2020 financial results and other business updates.

    The live webcast will be available under "Events and Presentations" in the Investors section of the Company's website at imaratx.com. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 7573255. A replay of the webcast will be archived on the Imara website following the presentation.

    About Imara

    Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.

    Cautionary Note Regarding Forward-Looking Statements

    Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements made by Dr. Ballal in this press release and statements relating to (i) the timing for reporting and the quality of data from the Phase 2a and OLE clinical trials evaluating IMR-687 in patients with sickle cell disease, (ii) the design and timing of the Company's Phase 2b clinical trials in patients with sickle cell disease and beta-thalassemia, (iii) the Company's development plans and preclinical studies of IMR-687 in heart failure with preserved ejection fraction; (iv) the Company's beliefs regarding the strength of its preclinical and clinical data, the therapeutic potential of IMR-687 and advancement of its clinical program, and (v) financial guidance regarding the Company's projected operating expenses and sufficiency of the Company's capital resources to fund its operations into mid-2022. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the impact of extraordinary external events, such as the risks and uncertainties resulting from the impact of the COVID-19 pandemic on the Company's business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities and ability to conduct and readout data from its ongoing Phase 2a clinical trial of IMR-687 in sickle cell disease and its ability to enroll, dose and readout data from its open label extension clinical trial of IMR-687 in sickle cell disease and its Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; the Company's ability to advance the development of IMR-687 under the timelines it projects in current and future clinical trials, demonstrate in any current and future clinical trials the requisite safety and efficacy of IMR-687, replicate scientific and non-clinical data in clinical trials, obtain and maintain necessary regulatory approvals, obtain, maintain and enforce necessary patent and other intellectual property protection, identify, enter into and maintain collaboration agreements with third parties, manage competition, manage expenses, raise the substantial additional capital needed to achieve its business objectives, attract and retain qualified personnel, and successfully execute on its business strategies; and other factors discussed in the "Risk Factors" section of the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Media Contact:

    Gina Nugent

    Ten Bridge Communications

    617-460-3579

    Investor Contact:

    Michael Gray

    617-835-4061

    com

    IMARA INC.

    CONDENSED CONSOLIDATED BALANCE SHEET DATA

    (in thousands)

    (Unaudited)

     September 30,

    2020
      December 31,

    2019
     
    Cash, cash equivalents and investments$96,089  $28,907 
    Working capital(1) 94,401   26,426 
    Total assets 100,175   33,298 
    Total liabilities 5,477   4,382 
    Convertible preferred stock    77,764 
    Accumulated deficit (84,595)  (54,753)
    Total stockholders' equity (deficit) 94,698   (48,848)

    (1)   Working capital is defined as current assets less current liabilities.





    IMARA INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except share and per share data)

    (Unaudited)

     Three Months Ended

    September 30,
      Nine Months Ended

    September 30,
     
     2020  2019  2020  2019 
    Operating expenses:               
    Research and development$9,533  $5,141  $23,195  $13,067 
    General and administrative 2,961   1,741   6,953   3,566 
    Total operating expenses 12,494   6,882   30,148   16,633 
    Loss from operations (12,494)  (6,882)  (30,148)  (16,633)
    Total other income:               
    Interest income 126   254   368   414 
    Other income (expense) (55)  6   (62)  6 
    Total other income (net) 71   260   306   420 
    Net loss$(12,423) $(6,622) $(29,842) $(16,213)
    Accretion of Series B convertible preferred stock       (7,858)   
    Net loss attributable to common stockholders—basic and diluted$(12,423) $(6,622) $(37,700) $(16,213)
    Weighted-average common shares outstanding—basic and diluted 17,349,813   702,510   12,696,368   702,510 
    Net loss per share attributable to common stockholders—basic and diluted$(0.72) $(9.43) $(2.97) $(23.08)

     

    Primary Logo

    View Full Article Hide Full Article
  3. BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Thursday, November 5, 2020, at 8:30 a.m. ET to discuss its third quarter 2020 financial results and recent business highlights.

    A live webcast will be available under "Events and Presentations" in the Investors section of the company's website at imaratx.com. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800-3873 (international) and referring to conference ID 7573255…

    BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Thursday, November 5, 2020, at 8:30 a.m. ET to discuss its third quarter 2020 financial results and recent business highlights.

    A live webcast will be available under "Events and Presentations" in the Investors section of the company's website at imaratx.com. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800-3873 (international) and referring to conference ID 7573255. A replay of the webcast will be archived on the Imara website following the presentation.

    About Imara

    Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com

    Media Contact:

    Gina Nugent

    Ten Bridge Communications

    617-460-3579

     

    Investor Contact:

    Michael Gray

    617-835-4061

    Primary Logo

    View Full Article Hide Full Article
  4. BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced dosing of the first patient in the company's Forte Phase 2b clinical trial of IMR-687 for patients with beta-thalassemia.

    "There are currently no approved oral therapies to increase fetal hemoglobin in beta-thalassemia, a rare inherited red blood cell disorder which if left untreated, causes severe anemia, enlarged spleen, skeletal abnormalities, organ failure and early death," said Perla Eleftheriou, Consultant Hematologist in the Red Cell Hematology department at University…

    BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced dosing of the first patient in the company's Forte Phase 2b clinical trial of IMR-687 for patients with beta-thalassemia.

    "There are currently no approved oral therapies to increase fetal hemoglobin in beta-thalassemia, a rare inherited red blood cell disorder which if left untreated, causes severe anemia, enlarged spleen, skeletal abnormalities, organ failure and early death," said Perla Eleftheriou, Consultant Hematologist in the Red Cell Hematology department at University College London Hospitals NHS Foundation Trust and Honorary Clinical Senior Lecturer at University College London and national lead investigator in the United Kingdom on the Forte trial. "We believe there is a clear rationale to expand development of IMR-687 to include beta-thalassemia and we look forward to working alongside multiple clinical centers globally to advance IMR-687 in the Forte clinical trial."

    "Dosing of the first patient in the Forte Phase 2b clinical trial marks an important milestone for Imara as we begin clinical evaluation of IMR-687 for the first time in patients with beta-thalassemia," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "Multiple preclinical studies show that treatment with IMR-687 enhances both the maturation and production of red blood cells in beta-thalassemia and we are looking forward to advancing this potentially transformative oral therapy for patients."

    Dr. Ballal continued, "Patient dosing in the Forte 2b clinical trial follows initiation of dosing this August in our Ardent Phase 2b clinical trial in patients with sickle cell disease. These advancements transform Imara into a company with a drug candidate in multiple indications across global, multi-center clinical trials. Managing the various clinical manifestations of beta-thalassemia and sickle cell disease is complex and patients around the world have few accessible treatment options. At Imara, we remain committed to working together with our clinical trial partners, investigators and the patient community to evaluate the therapeutic potential of IMR-687 as an oral, once-a-day, potentially disease-modifying treatment for these rare inherited blood disorders."

    The global, randomized, double-blind, placebo-controlled, multicenter Forte Phase 2b clinical trial will evaluate the safety and tolerability of IMR-687 in approximately 120 adult beta-thalassemia patients. Patient randomization will be stratified by transfusion dependence (TDT) or non-transfusion dependence (NTDT) and weight-based dosing will be employed to optimize drug exposure and tolerability. For TDT patients, the clinical trial will also evaluate the effect of IMR-687 versus placebo in reducing the average number of days between red blood cell transfusions and change in iron load rate as a result of transfusion. For NTDT patients, the effect of IMR-687 versus placebo on fetal hemoglobin as well as on anemia will also be evaluated. The Forte trial will also examine pharmacokinetic and additional exploratory efficacy endpoints. There are pre-specified interim analyses planned in the trial, with the first such interim analysis to be conducted when 30 patients have reached 24 weeks of treatment and an additional interim analysis being conducted when 30 patients have reached 36 weeks of treatment. For more information about the Forte trial visit https://www.clinicaltrials.gov/ct2/show/NCT04411082.

    About IMR-687

    IMR-687 is a highly selective and potent small molecule inhibitor of PDE9. PDE9 selectively degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule that plays a role in vascular biology. Lower levels of cGMP are found in people with SCD and beta-thalassemia and are associated with reduced blood flow, increased inflammation, greater cell adhesion and reduced nitric oxide mediated vasodilation.

    Blocking PDE9 acts to increase cGMP levels, which is associated with reactivation of fetal hemoglobin (HbF), a natural hemoglobin produced during fetal development. Increased levels of HbF in RBCs have been demonstrated to improve symptomology and substantially lower disease burden in both patients with SCD and patients with beta-thalassemia.

    About Beta-Thalassemia

    Beta-thalassemia, a hemoglobinopathy, is a rare inherited red blood cell disorder. Beta-thalassemia presents as a spectrum of disease, with patients categorized based on hemoglobin levels, genotype and clinical manifestations. If left untreated, the disease causes severe anemia, splenomegaly, skeletal abnormalities, organ failure and early death.



    The prevalence of beta-thalassemia globally is estimated to be 288,000, with an incidence of 60,000 births per year, and it is especially prevalent in developing countries of Africa, South Asia, Southeast Asia, the Mediterranean region and the Middle East. The total combined prevalence of beta thalassemia in the European Union and United States is estimated to be approximately 19,000 patients.

    About Imara

    Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com

    Cautionary Note Regarding Forward-Looking Statements

    Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements from Dr. Eleftheriou and Dr. Ballal and statements relating to the design of the Forte Phase 2b clinical trial and the Company's beliefs regarding the therapeutic potential of IMR-687 and advancement of its clinical program. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the impact of extraordinary external events, such as the risks and uncertainties resulting from the impact of the COVID-19 pandemic on the Company's business, operations, strategy, goals and anticipated milestones; the Company's ability to advance the development of IMR-687 under the timelines it projects in current and future clinical trials, demonstrate in any current and future clinical trials the requisite safety and efficacy of IMR-687, replicate scientific and non-clinical data in clinical trials, obtain and maintain necessary regulatory approvals, obtain, maintain and enforce necessary patent and other intellectual property protection, identify, enter into and maintain collaboration agreements with third parties, manage competition, manage expenses, raise the substantial additional capital needed to achieve its business objectives, attract and retain qualified personnel, and successfully execute on its business strategies; and other factors discussed in the "Risk Factors" section of the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Media Contact:

    Gina Nugent

    Ten Bridge Communications

    617-460-3579

    tions.com

    Investor Contact:

    Michael Gray

    617-835-4061

    Primary Logo

    View Full Article Hide Full Article
  5. BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the Company will participate in the following upcoming virtual investor conferences in September:

    • Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara will participate in two panel presentations at the Citi 15th Annual BioPharma Virtual Conference:
      -  Wednesday, September 9, 2020 at 4:15 p.m. ET - Challenges and Opportunities in Rare Disease Drug Development
      -  Thursday, September 10, 2020 at 4:15 p.m. ET - Benign Hematology 
    • Dr. Ballal will participate in…

    BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the Company will participate in the following upcoming virtual investor conferences in September:

    • Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara will participate in two panel presentations at the Citi 15th Annual BioPharma Virtual Conference:

      -  Wednesday, September 9, 2020 at 4:15 p.m. ET - Challenges and Opportunities in Rare Disease Drug Development

      -  Thursday, September 10, 2020 at 4:15 p.m. ET - Benign Hematology 
    • Dr. Ballal will participate in a virtual fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020 at 10:15 a.m. ET.

    A live webcast of the presentations will be available under "Events and Presentations" in the Investors section of the company's website at www.imaratx.com.

    About Imara

    Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.

    Media Contact:

    Gina Nugent

    Ten Bridge Communications

    617-460-3579

    Investor Contact:

    Michael Gray

    617-835-4061

    Primary Logo

    View Full Article Hide Full Article
View All IMARA Inc. News